Sjöquist P O, Marklund S L
Department of Pharmacology, Hässle Research Laboratories, Mölndal, Sweden.
Cardiovasc Res. 1992 Apr;26(4):347-50. doi: 10.1093/cvr/26.4.347.
The aim was to determine if endothelium associated extracellular superoxide dismutase type C (EC-SOD C) exerts any protective effect against cardiac damage induced by ischaemia and reperfusion.
Langendorff perfused rat hearts were subjected to 15 min global ischaemia followed by reperfusion. Prior to the ischaemia the hearts were perfused for 15 min with a buffer containing recombinant human EC-SOD C (rh-EC-SOD C, 20 mg.litre-1), or the corresponding vehicle, followed by extensive perfusion with SOD free medium.
In hearts receiving the vehicle, reperfusion was associated with a marked release of creatine kinase into the effluent [28 (SEM 1.5) IU.15 min-1, n = 5] and coronary flow measured 15 min after initiation of reperfusion was reduced by 68% compared to preischaemic flow. In hearts pretreated with EC-SOD C but washed with enzyme free buffer before being subjected to ischaemia, the creatine kinase release was significantly smaller, at 14(2.1) IU.min-1, n = 5 (p less than 0.001), and the reduction in coronary flow less extensive (54%, p less than 0.05, v vehicle). To demonstrate the binding of EC-SOD C to the endothelium, heparin, which releases EC-SOD C from the endothelial surfaces, was added to the perfusate 30 min after initiation of reperfusion. The same amount of EC-SOD C was released to the effluent from previously ischaemic hearts [(12.4(2) micrograms)] as from hearts not subjected to ischaemia [(13.8(1.4) micrograms)].
Recombinant human EC-SOD type C bound to the endothelial surface reduces the cardiac damage associated with ischaemia and reperfusion. The protective effect was evident both in terms of a reduction of biochemical markers of injury and a better preservation of postischaemic coronary flow. Furthermore, ischaemia and subsequent reperfusion did not cause any alteration in the binding capacity of EC-SOD C to the cardiac vasculature.
确定内皮相关的C型细胞外超氧化物歧化酶(EC-SOD C)是否对缺血再灌注诱导的心脏损伤具有任何保护作用。
采用Langendorff灌流的大鼠心脏,先进行15分钟全心缺血,然后再灌注。在缺血前,心脏用含有重组人EC-SOD C(rh-EC-SOD C,20mg·升-1)的缓冲液灌注15分钟,或用相应的溶剂灌注,随后用不含超氧化物歧化酶的培养基进行广泛灌流。
在接受溶剂灌注的心脏中,再灌注与肌酸激酶大量释放到流出液中有关[28(标准误1.5)IU·15分钟-1,n = 5],与缺血前流量相比,再灌注开始15分钟后测得的冠状动脉流量减少了68%。在用EC-SOD C预处理但在缺血前用无酶缓冲液冲洗的心脏中,肌酸激酶释放明显较少,为14(2.1)IU·分钟-1,n = 5(p<0.001),冠状动脉流量减少程度较小(54%,p<0.05,与溶剂组相比)。为了证明EC-SOD C与内皮的结合,在再灌注开始30分钟后,将能从内皮表面释放EC-SOD C的肝素加入到灌流液中。与未经历缺血的心脏[(13.8(1.4)微克)]相比,相同数量的EC-SOD C从先前缺血的心脏释放到流出液中[(12.4(2)微克)]。
结合在内皮表面的重组人C型超氧化物歧化酶可减少与缺血再灌注相关的心脏损伤。在减少损伤的生化标志物以及更好地保存缺血后冠状动脉流量方面,保护作用均很明显。此外,缺血及随后的再灌注并未导致EC-SOD C与心脏血管系统结合能力的任何改变。